UMAMI Bioworks, a Singapore-based cultivated seafood company, has broadened its cell cultivation platform to produce marine bioactives, starting with Polydeoxyribonucleotide (PDRN), a valuable component utilized in skincare, wound healing, and regenerative medicine. Traditionally sourced from salmon sperm, UMAMI Bioworks aims to address issues of supply consistency, ethical concerns, and biosecurity risks by developing cosmetic-grade PDRN in a bioreactor, with plans to introduce it to partners by Q4 before expanding into other product categories.
The global PDRN market is experiencing rapid growth, particularly in Asia-Pacific, driven by the demand in regenerative medicine, aesthetics, and skincare. UMAMI Bioworks believes that their ethical, scalable, and consistent production approach will not only tackle supply challenges but also facilitate market expansion by entering new territories and product segments, thereby increasing the overall market potential significantly. Their focus on supply stability, traceability, and batch consistency sets them apart initially, with plans to enhance competitiveness as they scale up production.
Regarding regulatory aspects, UMAMI Bioworks acknowledges the varying requirements for cosmetics bioactives across different markets. They are aligning their strategies with partners to navigate the regulatory pathways efficiently, ensuring compliance with product positioning and intended claims. The company anticipates having commercial-grade PDRN available for cosmetic applications by Q4, with subsequent launches in other categories based on market-specific timelines.
UMAMI Bioworks is leveraging its expertise in scalable bioprocesses, honed through cultivated seafood production, for the manufacturing and scale-up of PDRN. This involves growing proprietary marine cell lines under controlled conditions upstream and conducting nucleic acid extraction and purification downstream to meet stringent quality standards. Collaborations with contract manufacturing and extraction partners have been established for initial production volumes.
In managing resources, UMAMI Bioworks prioritizes areas that can generate short-term commercial gains while simultaneously building long-term platform value. Their current focus lies on advancing high-demand, high-value products like PDRN and other marine bioactives for cosmetics and wellness, alongside their core cultivated seafood initiatives. The company’s demonstration-scale facilities in Singapore and Malaysia are progressing well, supported by local partnerships aligned with strategic objectives.
Key Takeaways:
– UMAMI Bioworks is developing marine bioactives, starting with PDRN, to cater to the growing demand in skincare, wound healing, and regenerative medicine.
– Their approach emphasizes ethical, scalable production methods to overcome supply challenges and expand into new markets.
– Regulatory compliance and strategic partnerships play crucial roles in their commercialization plans for PDRN and other marine bioactives.
– Leveraging scalable bioprocess expertise, the company aims to ensure consistent quality and traceability in the production of marine bioactives.
Tags: regenerative medicine, bioprocess, bioreactor, downstream, upstream, regulatory
Read more on agfundernews.com
You might also like to read: Koji-Based Protein: The Future of Meat